Evidence map›Paper›PMID 38371918›Full record

ArticleBioinformatics advances2024

MMDRP: drug response prediction and biomarker discovery using multi-modal deep learning.

Farzan Taj, Lincoln D Stein

Abstract read
In one paragraph

Article in Bioinformatics advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Farzan TajDepartment of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A1, Canada.ORCID https://orcid.org/0000-0003-0966-5730
Lincoln D SteinDepartment of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A1, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Motivation: A major challenge in cancer care is that patients with similar demographics, tumor types, and medical histories can respond quite differently to the same drug regimens. This difference is largely explained by genetic and other molecular variabilities among the patients and their cancers. Efforts in the pharmacogenomics field are underway to understand better the relationship between the genome of the patient's healthy and tumor cells and their response to therapy. To advance this goal, research groups and consortia have undertaken large-scale systematic screening of panels of drugs across multiple cancer cell lines that have been molecularly profiled by genomics, proteomics, and similar techniques. These large data drug screening sets have been applied to the problem of drug response prediction (DRP), the challenge of predicting the response of a previously untested drug/cell-line combination. Although deep learning algorithms outperform traditional methods, there are still many challenges in DRP that ultimately result in these models' low generalizability and hampers their clinical application. Results: In this article, we describe a novel algorithm that addresses the major shortcomings of current DRP methods by combining multiple cell line characterization data, addressing drug response data skewness, and improving chemical compound representation. Availability and implementation: MMDRP is implemented as an open-source, Python-based, command-line program and is available at https://github.com/LincolnSteinLab/MMDRP.

Identifiers

PMID38371918
PMCPMC10872075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.